Helix BioMedix Inc
OTC:HXBM
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| US |
|
Helix BioMedix Inc
OTC:HXBM
|
606.7k USD |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
409.1B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
199B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
192.5B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
124.8B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
84.9B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
73.4B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.8B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -4 418 600% |
| 30th Percentile | -9.6% |
| Median | 3.1% |
| 70th Percentile | 11.3% |
| Max | 1 135 400% |
Other Profitability Ratios
Helix BioMedix Inc
Glance View
Helix BioMedix, Inc. is a biopharmaceutical company, which focuses on drug development for treatment of rare dermatological diseases, such as Xeroderma Pigmentosum. The company is headquartered in Bothell, Washington and currently employs 8 full-time employees. The company went IPO on 2000-07-25. The firm is focused on drug development for treatment of rare dermatological diseases. The firm's research and development (R&D) consists of a proprietary library of patented bioactive peptides based on the body’s innate immunity. The firm is focused on developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum (XP). HB4208 is a polypeptide DNA Damage Response (DDR) enzyme that is based on cellular repair pathways. HB4208 is in the preclinical development Phase. The firm is also engaged in identifying the precise peptides needed to stimulate cellular processes and control cell wall defense. Using the specific amino acid sequence for the desired activity, the Company's peptides work with targeted precision to provide optimal skin enhancing results in cosmeceutical and over the counter (OTC) formulations. Its peptides include Oligopeptide-10, Palmitoyl Hexapeptide-14 and others.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
Over the last 3 years, Helix BioMedix Inc’s Net Margin has increased from -948.8% to -125.1%. During this period, it reached a low of -994.7% on Mar 31, 2010 and a high of -106.5% on Mar 31, 2012.
